Rigel Pharmaceuticals (RIGL) Financials

$28.18 -0.22 (-0.77%)

Closing price 10/10/2025 04:00 PM Eastern

Extended Trading

$28.04 -0.14 (-0.50%)

As of 10/10/2025 07:56 PM Eastern

Annual Income Statements for Rigel Pharmaceuticals

This table shows Rigel Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-25	17
Consolidated Net Income / (Loss)	-59	-25	17
Net Income / (Loss) Continuing Operations	-59	-25	17
Total Pre-Tax Income	-59	-25	18
Total Operating Income	-56	-20	24
Total Gross Profit	118	110	161
Total Revenue	120	117	179
Operating Revenue	120	117	179
Total Cost of Revenue	1.75	7.11	19
Operating Cost of Revenue	1.75	7.11	19
Total Operating Expenses	174	130	136
Selling, General & Admin Expense	112	106	113
Research & Development Expense	60	25	23
Restructuring Charge	1.32	0.00	0.00
Total Other Income / (Expense), net	-3.02	-4.60	-5.83
Interest Expense	3.71	6.87	7.92
Interest & Investment Income	0.68	2.27	2.09
Income Tax Expense	0.00	0.00	0.88
Basic Earnings per Share	($3.44)	($1.44)	$0.99
Weighted Average Basic Shares Outstanding	17.05M	17.40M	17.58M
Diluted Earnings per Share	($3.44)	($1.44)	$0.99
Weighted Average Diluted Shares Outstanding	17.05M	17.40M	17.69M
Weighted Average Basic & Diluted Shares Outstanding	173.65M	175.38M	17.86M

This table shows Rigel Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-19	1.40	-14	-6.60	-5.69	0.74	-8.25	-1.03	12	14
Consolidated Net Income / (Loss)	-19	1.40	-14	-6.60	-5.69	0.74	-8.25	-1.03	12	14
Net Income / (Loss) Continuing Operations	-19	1.40	-14	-6.60	-5.69	0.74	-8.25	-1.03	12	14
Total Pre-Tax Income	-19	1.40	-14	-6.60	-5.69	0.74	-8.25	-1.03	12	15
Total Operating Income	-18	2.08	-13	-5.27	-4.47	1.97	-6.97	0.45	14	17
Total Gross Profit	22	51	25	26	27	32	28	34	47	52
Total Revenue	22	51	26	27	28	36	30	37	55	58
Operating Revenue	22	51	26	27	28	36	30	37	55	58
Total Cost of Revenue	0.25	0.34	0.98	1.08	1.27	3.79	2.03	2.81	8.03	5.79
Operating Cost of Revenue	0.25	0.34	0.98	1.08	1.27	3.79	2.03	2.81	8.03	5.79
Total Operating Expenses	41	49	38	31	31	30	34	34	33	35
Selling, General & Admin Expense	26	32	28	26	25	27	28	28	27	30
Research & Development Expense	15	15	10	4.77	6.48	3.19	6.03	5.54	6.18	5.63
Total Other Income / (Expense), net	-0.63	-0.68	-0.81	-1.33	-1.23	-1.23	-1.28	-1.48	-1.64	-1.43
Interest Expense	0.83	1.11	1.20	1.86	1.90	1.91	1.87	2.03	2.06	1.96
Interest & Investment Income	0.19	0.43	0.39	0.53	0.67	0.68	0.59	0.55	0.43	0.52
Basic Earnings per Share	($0.11)	$0.08	($0.08)	($0.38)	($0.33)	$0.04	($0.05)	($0.06)	$0.71	$0.82
Weighted Average Basic Shares Outstanding	172.84M	17.05M	173.57M	17.36M	17.44M	17.40M	175.20M	17.55M	17.60M	17.58M
Diluted Earnings per Share	($0.11)	$0.08	($0.08)	($0.38)	($0.33)	$0.04	($0.05)	($0.06)	$0.70	$0.82
Weighted Average Diluted Shares Outstanding	172.84M	17.05M	173.57M	17.36M	17.44M	17.40M	175.20M	17.55M	17.65M	17.69M
Basic & Diluted Earnings per Share	-	$0.08	-	-	-	$0.04	-	-	-	$0.82
Weighted Average Basic & Diluted Shares Outstanding	172.84M	173.65M	173.67M	174.36M	174.37M	175.38M	175.41M	17.59M	17.62M	17.86M

This table details how cash moves in and out of Rigel Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	5.57	8.33	24
Net Cash From Operating Activities	-74	-5.74	31
Net Cash From Continuing Operating Activities	-74	-5.74	31
Net Income / (Loss) Continuing Operations	-59	-25	17
Consolidated Net Income / (Loss)	-59	-25	17
Depreciation Expense	1.00	1.24	2.23
Amortization Expense	-0.06	-0.48	-0.71
Non-Cash Adjustments To Reconcile Net Income	13	9.07	12
Changes in Operating Assets and Liabilities, net	-29	9.52	0.15
Net Cash From Investing Activities	73	-4.30	4.13
Net Cash From Continuing Investing Activities	73	-4.30	4.13
Purchase of Property, Plant & Equipment	-	0.00	-0.04
Acquisitions	0.00	-15	-0.36
Purchase of Investments	-29	-31	-35
Sale of Property, Plant & Equipment	0.89	0.26	0.10
Sale and/or Maturity of Investments	101	42	40
Net Cash From Financing Activities	6.55	18	-12
Net Cash From Continuing Financing Activities	6.55	18	-12
Issuance of Debt	20	20	0.00
Issuance of Common Equity	2.12	1.05	1.96
Other Financing Activities, net	-15	-2.63	-14
Cash Interest Paid	2.50	5.85	7.04
Cash Income Taxes Paid	0.00	0.00	0.33

This table details how cash moves in and out of Rigel Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	2.67	-5.41	16	8.53	-3.40	-13	-7.21	10	16	5.05
Net Cash From Operating Activities	-13	-22	-4.07	5.93	-1.36	-6.24	-5.01	0.30	22	15
Net Cash From Continuing Operating Activities	-13	-22	-4.07	5.93	-1.36	-6.24	-5.01	0.30	22	15
Net Income / (Loss) Continuing Operations	-19	1.40	-14	-6.60	-5.69	0.74	-8.25	-1.03	12	14
Consolidated Net Income / (Loss)	-19	1.40	-14	-6.60	-5.69	0.74	-8.25	-1.03	12	14
Depreciation Expense	0.24	0.28	0.36	0.30	0.29	0.29	0.40	0.61	0.61	0.60
Amortization Expense	0.01	-0.18	-0.07	-0.05	-0.11	-0.26	-0.21	-0.16	-0.07	-0.28
Non-Cash Adjustments To Reconcile Net Income	2.50	4.41	3.11	2.22	1.92	1.82	5.13	2.53	2.62	2.03
Changes in Operating Assets and Liabilities, net	2.99	-28	6.07	10	2.23	-8.83	-2.10	-1.65	6.10	-2.20
Net Cash From Investing Activities	10	19	0.78	2.97	-1.17	-6.87	0.31	11	3.80	-11
Net Cash From Continuing Investing Activities	10	19	0.78	2.97	-1.17	-6.87	0.31	11	3.80	-11
Purchase of Property, Plant & Equipment	-0.19	-	-	-	-	-	-	-	-	-0.03
Purchase of Investments	-19	-2.85	0.00	-8.78	-9.44	-13	-7.80	-7.55	-2.21	-18
Sale of Property, Plant & Equipment	0.28	0.35	0.13	-	0.02	0.11	0.00	-	0.03	0.07
Sale and/or Maturity of Investments	29	21	16	12	8.25	6.00	8.25	19	6.00	6.75
Net Cash From Financing Activities	5.51	-2.10	19	-0.37	-0.87	0.49	-2.51	-0.75	-9.84	1.47
Net Cash From Continuing Financing Activities	5.51	-2.10	19	-0.37	-0.87	0.49	-2.51	-0.75	-9.84	1.47
Issuance of Common Equity	-	0.59	0.00	0.55	0.01	0.49	0.09	0.25	0.16	1.47
Cash Interest Paid	0.60	0.95	1.01	1.47	1.68	1.68	1.68	1.77	1.84	1.75

This table presents Rigel Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	134	117	164
Total Current Assets	116	99	135
Cash & Equivalents	24	33	57
Short-Term Investments	34	24	21
Accounts Receivable	40	31	42
Inventories, net	9.12	5.52	6.00
Prepaid Expenses	8.26	6.26	10
Plant, Property, & Equipment, net	0.86	0.17	0.09
Total Noncurrent Assets	18	18	29
Goodwill	15	14	27
Other Noncurrent Operating Assets	2.57	3.92	1.68
Total Liabilities & Shareholders' Equity	134	117	164
Total Liabilities	148	146	161
Total Current Liabilities	65	53	63
Short-Term Debt	0.00	7.23	7.27
Accounts Payable	23	7.14	3.34
Accrued Expenses	14	8.85	14
Current Deferred Revenue	1.37	1.36	1.36
Current Employee Benefit Liabilities	8.87	8.68	10
Other Current Liabilities	18	20	27
Total Noncurrent Liabilities	83	93	97
Long-Term Debt	39	52	52
Capital Lease Obligations	0.97	0.29	0.00
Other Noncurrent Operating Liabilities	42	40	45
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-14	-29	3.29
Total Preferred & Common Equity	-14	-29	3.29
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-14	-29	3.29
Common Stock	1,369	1,379	1,393
Retained Earnings	-1,382	-1,408	-1,390
Accumulated Other Comprehensive Income / (Loss)	-0.15	0.01	0.01

This table presents Rigel Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	116	124	117	115	127	128	139
Total Current Assets	110	107	101	95	92	95	106
Cash & Equivalents	30	40	49	45	26	36	52
Short-Term Investments	52	18	16	17	24	13	9.42
Accounts Receivable	16	29	21	24	28	29	31
Inventories, net	7.12	11	11	6.11	6.58	8.06	4.78
Prepaid Expenses	6.16	7.87	4.97	3.02	8.85	8.66	9.99
Plant, Property, & Equipment, net	1.69	0.29	0.22	0.19	0.14	0.12	0.10
Total Noncurrent Assets	3.48	16	16	20	34	34	33
Goodwill	-	15	14	14	29	28	28
Other Noncurrent Operating Assets	3.48	1.67	1.54	5.96	5.03	5.30	5.17
Total Liabilities & Shareholders' Equity	116	124	117	115	127	128	139
Total Liabilities	135	148	145	147	158	158	154
Total Current Liabilities	47	46	44	48	73	59	54
Short-Term Debt	-	-	-	-	15	0.00	0.00
Accounts Payable	2.72	6.30	5.24	8.00	9.28	6.13	3.82
Accrued Expenses	25	12	11	11	9.56	11	14
Current Deferred Revenue	1.37	1.37	1.36	1.36	1.36	1.36	1.36
Current Employee Benefit Liabilities	8.77	5.66	6.74	8.09	5.25	6.37	7.92
Other Current Liabilities	9.23	20	20	20	33	34	28
Total Noncurrent Liabilities	88	102	101	99	85	100	100
Long-Term Debt	39	59	60	60	45	60	60
Capital Lease Obligations	0.00	0.80	0.63	0.47	0.10	0.00	0.00
Other Noncurrent Operating Liabilities	49	42	41	39	40	40	40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-20	-24	-28	-32	-32	-30	-15
Total Preferred & Common Equity	-20	-24	-28	-32	-32	-30	-15
Total Common Equity	-20	-24	-28	-32	-32	-30	-15
Common Stock	1,364	1,372	1,375	1,376	1,384	1,387	1,390
Retained Earnings	-1,384	-1,396	-1,403	-1,408	-1,416	-1,417	-1,404
Accumulated Other Comprehensive Income / (Loss)	-0.29	-0.03	-0.03	-0.02	-0.01	-0.01	0.01

This table displays calculated financial ratios and metrics derived from Rigel Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-19.43%	-2.79%	53.38%
EBITDA Growth	-394.39%	63.87%	230.30%
EBIT Growth	-344.54%	63.11%	218.06%
NOPAT Growth	-344.54%	63.11%	260.57%
Net Income Growth	-226.97%	57.16%	169.69%
EPS Growth	-226.97%	57.16%	168.75%
Operating Cash Flow Growth	-1,354.81%	92.21%	647.99%
Free Cash Flow Firm Growth	-212.53%	75.36%	158.31%
Invested Capital Growth	57.52%	18.19%	44.13%
Revenue Q/Q Growth	34.54%	-11.70%	13.85%
EBITDA Q/Q Growth	29.71%	-0.95%	139.68%
EBIT Q/Q Growth	29.73%	-0.55%	154.57%
NOPAT Q/Q Growth	29.73%	-0.55%	142.36%
Net Income Q/Q Growth	29.10%	-2.72%	350.53%
EPS Q/Q Growth	29.10%	-2.72%	350.00%
Operating Cash Flow Q/Q Growth	-3.98%	73.18%	193.35%
Free Cash Flow Firm Q/Q Growth	-21.65%	52.49%	236.47%
Invested Capital Q/Q Growth	49.36%	24.57%	10.23%
Profitability Metrics	-	-	-
Gross Margin	98.55%	93.92%	89.60%
EBITDA Margin	-45.42%	-16.88%	14.34%
Operating Margin	-46.20%	-17.53%	13.49%
EBIT Margin	-46.20%	-17.53%	13.49%
Profit (Net Income) Margin	-48.71%	-21.47%	9.75%
Tax Burden Percent	100.00%	100.00%	95.20%
Interest Burden Percent	105.44%	122.45%	75.92%
Effective Tax Rate	0.00%	0.00%	4.80%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-699.05%	118.75%	-137.92%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-36.84%	-16.29%	17.21%
Return on Assets (ROA)	-38.84%	-19.95%	12.44%
Return on Common Equity (ROCE)	-699.05%	118.75%	-137.92%
Return on Equity Simple (ROE_SIMPLE)	430.18%	87.60%	531.78%
Net Operating Profit after Tax (NOPAT)	-39	-14	23
NOPAT Margin	-32.34%	-12.27%	12.85%
Net Nonoperating Expense Percent (NNEP)	-32.25%	-144.92%	-75.53%
Return On Investment Capital (ROIC_SIMPLE)	-145.07%	-45.91%	36.58%
Cost of Revenue to Revenue	1.45%	6.08%	10.40%
SG&A Expenses to Revenue	93.52%	90.47%	63.06%
R&D to Revenue	50.13%	20.98%	13.04%
Operating Expenses to Revenue	144.74%	111.45%	76.10%
Earnings before Interest and Taxes (EBIT)	-56	-20	24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-55	-20	26
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	90.11
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.16	2.16	1.65
Price to Earnings (P/E)	0.00	0.00	16.95
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	5.90%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.01	2.19	1.55
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	10.84
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	11.52
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	12.10
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	8.85
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	23.83
Leverage & Solvency	-	-	-
Debt to Equity	-2.97	-2.09	18.15
Long-Term Debt to Equity	-2.97	-1.84	15.94
Financial Leverage	-7.28	0.35	0.58
Leverage Ratio	18.00	-5.95	-11.09
Compound Leverage Factor	18.98	-7.29	-8.42
Debt to Total Capital	150.80%	191.68%	94.78%
Short-Term Debt to Total Capital	0.00%	23.14%	11.55%
Long-Term Debt to Total Capital	150.80%	168.54%	83.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	-50.80%	-91.68%	5.22%
Debt to EBITDA	-0.74	-3.04	2.32
Net Debt to EBITDA	0.33	-0.15	-0.69
Long-Term Debt to EBITDA	-0.74	-2.67	2.04
Debt to NOPAT	-1.04	-4.18	2.59
Net Debt to NOPAT	0.46	-0.21	-0.77
Long-Term Debt to NOPAT	-1.04	-3.67	2.28
Altman Z-Score	-13.38	-14.88	-8.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.78	1.86	2.13
Quick Ratio	1.51	1.64	1.88
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-81	-20	12
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-21.96	-2.92	1.48
Operating Cash Flow to Interest Expense	-19.90	-0.84	3.97
Operating Cash Flow Less CapEx to Interest Expense	-19.66	-0.80	3.98
Efficiency Ratios	-	-	-
Asset Turnover	0.80	0.93	1.28
Accounts Receivable Turnover	4.31	3.30	4.97
Inventory Turnover	0.22	0.97	3.24
Fixed Asset Turnover	79.08	228.73	1,395.16
Accounts Payable Turnover	0.13	0.48	3.56
Days Sales Outstanding (DSO)	84.68	110.66	73.46
Days Inventory Outstanding (DIO)	1,641.77	375.78	112.79
Days Payable Outstanding (DPO)	2,744.60	761.06	102.58
Cash Conversion Cycle (CCC)	-1,018.15	-274.62	83.67
Capital & Investment Metrics	-	-	-
Invested Capital	-31	-26	-14
Invested Capital Turnover	-2.28	-4.09	-8.95
Increase / (Decrease) in Invested Capital	43	5.71	11
Enterprise Value (EV)	241	256	279
Market Capitalization	259	253	296
Book Value per Share	($0.08)	($0.16)	$0.19
Tangible Book Value per Share	($0.17)	($0.24)	($1.35)
Total Capital	27	31	63
Total Debt	40	60	60
Total Long-Term Debt	40	53	52
Net Debt	-18	2.95	-18
Capital Expenditures (CapEx)	-0.89	-0.26	-0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.51	-3.71	1.76
Debt-free Net Working Capital (DFNWC)	51	53	79
Net Working Capital (NWC)	51	46	72
Net Nonoperating Expense (NNE)	20	11	5.55
Net Nonoperating Obligations (NNO)	-18	2.95	-18
Total Depreciation and Amortization (D&A)	0.94	0.76	1.52
Debt-free, Cash-free Net Working Capital to Revenue	-6.25%	-3.17%	0.98%
Debt-free Net Working Capital to Revenue	42.16%	45.54%	44.11%
Net Working Capital to Revenue	42.16%	39.36%	40.05%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.40)	($1.40)	$0.99
Adjusted Weighted Average Basic Shares Outstanding	17.24M	17.40M	17.58M
Adjusted Diluted Earnings per Share	($3.40)	($1.40)	$0.99
Adjusted Weighted Average Diluted Shares Outstanding	17.24M	17.40M	17.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	17.37M	17.54M	17.86M
Normalized Net Operating Profit after Tax (NOPAT)	-38	-14	23
Normalized NOPAT Margin	-31.57%	-12.27%	12.85%
Pre Tax Income Margin	-48.71%	-21.47%	10.24%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-14.99	-2.98	3.06
NOPAT to Interest Expense	-10.49	-2.09	2.91
EBIT Less CapEx to Interest Expense	-14.74	-2.94	3.06
NOPAT Less CapEx to Interest Expense	-10.25	-2.05	2.92
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Rigel Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.02%	151.25%	55.78%	-9.84%	25.54%	-30.20%	13.29%	37.03%	96.58%	60.92%
EBITDA Growth	6.65%	110.45%	52.16%	60.34%	76.43%	-8.47%	45.55%	117.96%	441.23%	749.57%
EBIT Growth	6.99%	109.71%	51.54%	59.38%	75.74%	-5.44%	45.26%	108.49%	414.80%	747.15%
NOPAT Growth	6.99%	113.87%	51.54%	59.38%	75.74%	-5.44%	45.26%	108.49%	549.72%	747.15%
Net Income Growth	9.14%	106.19%	50.68%	51.08%	70.10%	-47.39%	39.07%	84.39%	318.22%	1,845.86%
EPS Growth	8.33%	106.19%	50.00%	51.08%	70.10%	-47.39%	37.50%	84.21%	312.12%	1,950.00%
Operating Cash Flow Growth	-29.17%	-14.79%	84.11%	145.93%	89.78%	71.52%	-23.05%	-94.91%	1,695.22%	332.42%
Free Cash Flow Firm Growth	-142.38%	-161.19%	-151.35%	-199.75%	-27.02%	90.74%	89.36%	63.30%	87.08%	241.96%
Invested Capital Growth	15.74%	57.52%	68.07%	48.78%	45.07%	18.19%	5.31%	40.12%	53.06%	44.13%
Revenue Q/Q Growth	-24.85%	128.82%	-49.16%	3.13%	4.64%	27.22%	-17.48%	24.74%	50.12%	4.14%
EBITDA Q/Q Growth	-43.52%	112.03%	-669.41%	59.66%	14.73%	146.73%	-438.72%	113.31%	1,520.20%	16.34%
EBIT Q/Q Growth	-41.94%	111.30%	-712.07%	58.61%	15.23%	144.03%	-454.32%	106.42%	3,044.52%	18.49%
NOPAT Q/Q Growth	-41.94%	116.14%	-528.45%	58.61%	15.23%	162.90%	-348.03%	106.42%	4,392.17%	18.49%
Net Income Q/Q Growth	-41.10%	107.36%	-1,066.17%	51.24%	13.76%	112.95%	-1,219.00%	87.51%	1,305.92%	15.46%
EPS Q/Q Growth	-37.50%	107.36%	-900.00%	51.24%	13.76%	112.95%	0.00%	-20.00%	1,266.67%	17.14%
Operating Cash Flow Q/Q Growth	-3.02%	-64.72%	81.40%	245.56%	-122.92%	-359.16%	19.66%	106.02%	7,078.48%	-33.10%
Free Cash Flow Firm Q/Q Growth	-113.01%	-65.31%	-41.32%	39.76%	9.74%	87.94%	-62.26%	-107.84%	68.21%	232.42%
Invested Capital Q/Q Growth	1.59%	49.36%	27.93%	-42.58%	-5.55%	24.57%	16.58%	9.83%	17.26%	10.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.88%	99.33%	96.25%	96.00%	95.49%	89.41%	93.14%	92.38%	85.49%	89.95%
EBITDA Margin	-81.01%	4.26%	-47.70%	-18.66%	-15.21%	5.59%	-22.93%	2.45%	26.39%	29.49%
Operating Margin	-82.12%	4.05%	-48.81%	-19.59%	-15.87%	5.49%	-23.59%	1.21%	25.41%	28.92%
EBIT Margin	-82.12%	4.05%	-48.81%	-19.59%	-15.87%	5.49%	-23.59%	1.21%	25.41%	28.92%
Profit (Net Income) Margin	-84.95%	2.73%	-51.92%	-24.55%	-20.23%	2.06%	-27.92%	-2.80%	22.46%	24.90%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	94.21%
Interest Burden Percent	103.45%	67.39%	106.37%	125.31%	127.48%	37.49%	118.39%	-230.43%	88.37%	91.40%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-553.79%	-699.05%	511.64%	237.62%	94.55%	118.75%	70.81%	49.05%	-16.70%	-137.92%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-48.58%	3.23%	-46.39%	-20.25%	-18.19%	5.11%	-22.70%	1.29%	31.42%	36.87%
Return on Assets (ROA)	-50.26%	2.18%	-49.35%	-25.37%	-23.19%	1.91%	-26.87%	-2.97%	27.77%	31.75%
Return on Common Equity (ROCE)	-553.79%	-699.05%	511.64%	237.62%	94.55%	118.75%	70.81%	49.05%	-16.70%	-137.92%
Return on Equity Simple (ROE_SIMPLE)	416.53%	0.00%	184.13%	134.35%	76.73%	0.00%	62.52%	47.58%	-26.52%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	2.08	-8.91	-3.69	-3.13	1.97	-4.88	0.31	14	17
NOPAT Margin	-57.48%	4.05%	-34.17%	-13.71%	-11.11%	5.49%	-16.51%	0.85%	25.41%	28.92%
Net Nonoperating Expense Percent (NNEP)	-7.44%	-1.11%	-12.17%	-9.18%	-11.56%	-16.57%	56.82%	41.74%	-91.39%	-31.51%
Return On Investment Capital (ROIC_SIMPLE)	-	7.76%	-	-	-	6.29%	-	-	-	26.45%
Cost of Revenue to Revenue	1.12%	0.67%	3.75%	4.00%	4.51%	10.59%	6.86%	7.62%	14.51%	10.05%
SG&A Expenses to Revenue	115.56%	62.74%	106.36%	97.84%	88.35%	75.02%	96.33%	76.13%	48.90%	51.25%
R&D to Revenue	65.44%	29.96%	38.70%	17.75%	23.01%	8.90%	20.40%	15.04%	11.18%	9.78%
Operating Expenses to Revenue	181.00%	95.28%	145.06%	115.59%	111.36%	83.92%	116.73%	91.17%	60.07%	61.03%
Earnings before Interest and Taxes (EBIT)	-18	2.08	-13	-5.27	-4.47	1.97	-6.97	0.45	14	17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-18	2.18	-12	-5.02	-4.28	2.00	-6.77	0.90	15	17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	90.11
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.28	2.16	1.77	1.77	1.42	2.16	2.16	1.11	1.81	1.65
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	73.35	16.95
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.36%	5.90%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.81	2.01	1.78	1.74	1.41	2.19	2.24	1.19	1.80	1.55
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.41	10.84
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.82	11.52
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.82	12.10
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.41	8.85
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23.83
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.99	-2.97	-2.49	-2.14	-1.89	-2.09	-1.89	-2.00	-4.08	18.15
Long-Term Debt to Equity	-1.99	-2.97	-2.49	-2.14	-1.89	-1.84	-1.42	-2.00	-4.08	15.94
Financial Leverage	-5.54	-7.28	4.36	2.00	0.86	0.35	-0.21	-0.11	0.08	0.58
Leverage Ratio	10.13	18.00	-15.62	-7.71	-4.47	-5.95	-4.47	-4.23	-5.48	-11.09
Compound Leverage Factor	10.48	12.13	-16.61	-9.66	-5.70	-2.23	-5.29	9.75	-4.84	-10.14
Debt to Total Capital	201.02%	150.80%	167.33%	187.62%	212.52%	191.68%	212.63%	200.46%	132.43%	94.78%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	23.14%	52.56%	0.00%	0.00%	11.55%
Long-Term Debt to Total Capital	201.02%	150.80%	167.33%	187.62%	212.52%	168.54%	160.07%	200.46%	132.43%	83.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-101.02%	-50.80%	-67.33%	-87.62%	-112.52%	-91.68%	-112.63%	-100.46%	-32.43%	5.22%
Debt to EBITDA	-0.51	-0.74	-1.47	-1.80	-3.08	-3.04	-4.25	-7.33	5.57	2.32
Net Debt to EBITDA	0.54	0.33	-0.04	0.12	0.11	-0.15	-0.73	-1.30	-0.13	-0.69
Long-Term Debt to EBITDA	-0.51	-0.74	-1.47	-1.80	-3.08	-2.67	-3.20	-7.33	5.57	2.04
Debt to NOPAT	-0.71	-1.04	-2.05	-2.51	-4.22	-4.18	-5.80	-9.46	6.29	2.59
Net Debt to NOPAT	0.76	0.46	-0.06	0.17	0.16	-0.21	-0.99	-1.68	-0.14	-0.77
Long-Term Debt to NOPAT	-0.71	-1.04	-2.05	-2.51	-4.22	-3.67	-4.36	-9.46	6.29	2.28
Altman Z-Score	-14.95	-11.96	-13.58	-14.33	-14.82	-14.25	-13.73	-13.54	-11.08	-8.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.34	1.78	2.35	2.29	1.97	1.86	1.26	1.62	1.96	2.13
Quick Ratio	2.06	1.51	1.93	1.93	1.78	1.64	1.05	1.33	1.69	1.88
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-24	-40	-57	-34	-31	-3.75	-6.08	-13	-4.02	5.32
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-29.62	-36.53	-47.47	-18.49	-16.36	-1.96	-3.24	-6.23	-1.95	2.72
Operating Cash Flow to Interest Expense	-16.10	-19.79	-3.38	3.18	-0.72	-3.27	-2.68	0.15	10.52	7.42
Operating Cash Flow Less CapEx to Interest Expense	-15.99	-19.48	-3.28	3.18	-0.70	-3.21	-2.68	0.15	10.54	7.44
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.59	0.80	0.95	1.03	1.15	0.93	0.96	1.06	1.24	1.28
Accounts Receivable Turnover	5.86	4.31	5.81	6.66	6.78	3.30	4.23	5.24	5.82	4.97
Inventory Turnover	0.27	0.22	0.29	0.31	0.55	0.97	0.92	1.05	3.06	3.24
Fixed Asset Turnover	41.10	79.08	106.47	123.74	140.52	228.73	554.59	789.70	1,089.79	1,395.16
Accounts Payable Turnover	0.65	0.13	0.48	0.72	0.68	0.48	1.05	1.74	2.82	3.56
Days Sales Outstanding (DSO)	62.31	84.68	62.82	54.78	53.87	110.66	86.25	69.64	62.72	73.46
Days Inventory Outstanding (DIO)	1,363.55	1,641.77	1,249.90	1,173.41	659.23	375.78	394.98	347.67	119.45	112.79
Days Payable Outstanding (DPO)	565.13	2,744.60	764.26	510.43	534.24	761.06	348.33	209.81	129.51	102.58
Cash Conversion Cycle (CCC)	860.73	-1,018.15	548.46	717.76	178.86	-274.62	132.90	207.50	52.66	83.67
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-62	-31	-23	-32	-34	-26	-21	-19	-16	-14
Invested Capital Turnover	-1.32	-2.28	-2.77	-2.66	-2.76	-4.09	-5.46	-5.05	-6.29	-8.95
Increase / (Decrease) in Invested Capital	12	43	48	31	28	5.71	1.20	13	18	11
Enterprise Value (EV)	162	241	231	220	186	256	270	155	283	279
Market Capitalization	204	259	229	224	188	253	260	144	285	296
Book Value per Share	($0.11)	($0.08)	($0.14)	($0.16)	($0.18)	($0.16)	($0.18)	($0.17)	($0.83)	$0.19
Tangible Book Value per Share	($0.11)	($0.17)	($0.22)	($0.24)	($0.26)	($0.24)	($0.35)	($0.33)	($2.41)	($1.35)
Total Capital	20	27	36	32	28	31	28	30	45	63
Total Debt	39	40	60	60	60	60	60	60	60	60
Total Long-Term Debt	39	40	60	60	60	53	45	60	60	52
Net Debt	-42	-18	1.62	-4.16	-2.23	2.95	10	11	-1.35	-18
Capital Expenditures (CapEx)	-0.09	-0.35	-0.13	0.00	-0.02	-0.11	0.00	0.00	-0.03	-0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-7.51	2.79	-7.46	-16	-3.71	-15	-13	-8.96	1.76
Debt-free Net Working Capital (DFNWC)	63	51	61	57	47	53	34	36	52	79
Net Working Capital (NWC)	63	51	61	57	47	46	19	36	52	72
Net Nonoperating Expense (NNE)	6.15	0.68	4.63	2.91	2.57	1.23	3.37	1.34	1.64	2.31
Net Nonoperating Obligations (NNO)	-42	-18	1.62	-4.16	-2.23	2.95	10	11	-1.35	-18
Total Depreciation and Amortization (D&A)	0.25	0.11	0.29	0.25	0.19	0.03	0.20	0.45	0.54	0.33
Debt-free, Cash-free Net Working Capital to Revenue	-20.66%	-6.25%	2.15%	-5.89%	-11.79%	-3.17%	-12.86%	-10.00%	-5.69%	0.98%
Debt-free Net Working Capital to Revenue	70.69%	42.16%	47.43%	44.93%	35.32%	45.54%	28.31%	27.69%	33.12%	44.11%
Net Working Capital to Revenue	70.69%	42.16%	47.43%	44.93%	35.32%	39.36%	16.03%	27.69%	33.12%	40.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.10)	$0.80	($0.80)	($0.40)	($0.30)	$0.40	($0.50)	($0.06)	$0.71	$0.82
Adjusted Weighted Average Basic Shares Outstanding	17.28M	1.70M	17.36M	17.37M	17.44M	1.74M	17.52M	17.55M	17.60M	17.58M
Adjusted Diluted Earnings per Share	($1.10)	$0.80	($0.80)	($0.40)	($0.30)	$0.40	($0.50)	($0.06)	$0.70	$0.82
Adjusted Weighted Average Diluted Shares Outstanding	17.28M	1.70M	17.36M	17.37M	17.44M	1.74M	17.52M	17.55M	17.65M	17.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.80	$0.00	$0.00	$0.00	$0.40	$0.00	$0.00	$0.00	$0.82
Adjusted Weighted Average Basic & Diluted Shares Outstanding	17.28M	17.37M	17.37M	17.44M	17.44M	17.54M	17.54M	17.59M	17.62M	17.86M
Normalized Net Operating Profit after Tax (NOPAT)	-13	1.46	-8.91	-3.69	-3.13	1.38	-4.88	0.31	9.84	12
Normalized NOPAT Margin	-57.48%	2.84%	-34.17%	-13.71%	-11.11%	3.85%	-16.51%	0.85%	17.79%	20.24%
Pre Tax Income Margin	-84.95%	2.73%	-51.92%	-24.55%	-20.23%	2.06%	-27.92%	-2.80%	22.46%	26.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-22.28	1.88	-10.57	-2.83	-2.35	1.03	-3.72	0.22	6.82	8.52
NOPAT to Interest Expense	-15.60	1.88	-7.40	-1.98	-1.65	1.03	-2.60	0.15	6.82	8.52
EBIT Less CapEx to Interest Expense	-22.17	2.19	-10.46	-2.83	-2.34	1.09	-3.72	0.22	6.84	8.54
NOPAT Less CapEx to Interest Expense	-15.49	2.19	-7.29	-1.98	-1.63	1.09	-2.60	0.15	6.84	8.54
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Rigel Pharmaceuticals (NASDAQ: RIGL) Recent Financial Analysis Summary:

Rigel Pharmaceuticals has shown a trend of increasing revenues and improving profitability over the most recent quarters of 2024 compared to 2023 and earlier periods. The company’s operating revenues have steadily risen from around $26 million in Q1 2023 to nearly $58 million by Q4 2024. This growth has translated into a positive net income in the last two quarters, reversing prior quarterly losses experienced in 2023 and early 2024.

Key Positive Developments:

Revenue growth: Operating revenue increased significantly from $26.07 million in Q1 2023 to $57.6 million in Q4 2024.
Profitability turnaround: Net income turned positive with $14.3 million in Q4 2024 compared to net losses in 2023, showing operational improvements.
Gross profit expansion: Gross profit rose notably, with $51.8 million in Q4 2024 compared to $25.1 million in Q1 2023, indicating improved cost management or better pricing.
Operating income improvement: Operating income swung positive to about $16.7 million in Q4 2024 from negative $12.7 million in Q1 2023.
Operating cash flows: Net cash from continuing operating activities consistently turned positive and strong, e.g., $14.5 million in Q4 2024 and $21.7 million in Q3 2024, indicating solid cash generation.
Equity financing: Modest issuances of common equity in recent quarters helped bolster liquidity without excessive dilution (e.g., $1.47 million in Q4 2024).
Careful investment activity: Sale and maturity of investments in recent quarters have added cash inflows, offsetting purchases, supporting liquidity management.

Neutral Factors to Watch:

High SG&A and R&D expenses: Selling, general, and administrative expenses along with research and development remain substantial but show some moderation relative to revenue growth.
Stable share count: Weighted average shares outstanding have remained fairly steady around 17.5-17.7 million, supporting EPS comparability.
Capital expenditures are relatively low, indicating little expansion in fixed assets.

Potential Headwinds and Risks:

Significant interest expenses: Interest expenses remain in the $1.2-$2.1 million range per quarter, reducing net income and cash flow, linked to high long-term debt levels.
Negative equity position: Total common equity remains negative (e.g., -$31.7 million in Q1 2024 and -$29.9 million in Q2 2024), signaling cumulative losses and financial leverage concerns.
Large long-term debt: Long-term debt stands around $59-60 million throughout 2023-2024, creating ongoing debt servicing obligations and financial risk.
Volatile cash from financing activities: Wide swings in financing cash flows, including large repayments and issuances, contribute to financial uncertainty.
Net losses in most of 2023 and early 2024 before recent recovery indicate past operational challenges.

Summary: Rigel Pharmaceuticals has demonstrated encouraging top-line growth and a return to profitability in late 2024 after a difficult 2023 and early 2024 characterized by losses and weak cash flows. Strong operating cash flow generation and revenue expansion highlight improving business fundamentals. However, the company continues to face significant financial leverage, sustained interest expenses, and a negative equity base, which may pose risks to financial stability. Investors should weigh these improving operational metrics against the company’s debt profile and past volatility.

10/11/25 10:42 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

When does Rigel Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Rigel Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Rigel Pharmaceuticals' net income changed over the last 2 years?

Rigel Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $17.49 million in 2024, falling from -$58.57 million in 2022. The previous period was -$25.09 million in 2023. See where experts think Rigel Pharmaceuticals is headed by visiting Rigel Pharmaceuticals' forecast page.

What is Rigel Pharmaceuticals' operating income?

Rigel Pharmaceuticals' total operating income in 2024 was $24.19 million, based on the following breakdown:

Total Gross Profit: $160.63 million
Total Operating Expenses: $136.44 million

How has Rigel Pharmaceuticals' revenue changed over the last 2 years?

Over the last 2 years, Rigel Pharmaceuticals' total revenue changed from $120.24 million in 2022 to $179.28 million in 2024, a change of 49.1%.

How much debt does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals' total liabilities were at $160.69 million at the end of 2024, a 10.2% increase from 2023, and a 8.7% increase since 2022.

How much cash does Rigel Pharmaceuticals have?

In the past 2 years, Rigel Pharmaceuticals' cash and equivalents has ranged from $24.46 million in 2022 to $56.75 million in 2024, and is currently $56.75 million as of their latest financial filing in 2024.

How has Rigel Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Rigel Pharmaceuticals' book value per share changed from -0.08 in 2022 to 0.19 in 2024, a change of -336.9%.

Related Companies

This page (NASDAQ:RIGL) was last updated on 10/11/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Financials

Annual Income Statements for Rigel Pharmaceuticals

Quarterly Income Statements for Rigel Pharmaceuticals

Annual Cash Flow Statements for Rigel Pharmaceuticals

Quarterly Cash Flow Statements for Rigel Pharmaceuticals

Annual Balance Sheets for Rigel Pharmaceuticals

Quarterly Balance Sheets for Rigel Pharmaceuticals

Annual Metrics And Ratios for Rigel Pharmaceuticals

Quarterly Metrics And Ratios for Rigel Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools